Time-Dependent Changes of Plasma Concentrations of Angiopoietins, Vascular Endothelial Growth Factor, and Soluble Forms of Their Receptors in Nonsmall Cell Lung Cancer Patients Following Surgical Resection

Even when patients with nonsmall cell lung cancer undergo surgical resection at an early stage, recurrent disease often impairs the clinical outcome. There are numerous causes potentially responsible for a relapse of the disease, one of them being extensive angiogenesis. The balance of at least two systems, VEGF VEGFR and Ang Tie, regulates vessel formation. The aim of this study was to determine the impact of surgery on the plasma levels of the main angiogenic factors during the first month after surgery in nonsmall cell lung cancer patients. The study group consisted of 37 patients with stage I nonsmall cell lung cancer. Plasma concentrations of Ang1, Ang2, sTie2, VEGF, and sVEGF R1 were evaluated by ELISA three times: before surgical resection and on postoperative days 7 and 30. The median of Ang2 and VEGF concentrations increased on postoperative day 7 and decreased on day 30. On the other hand, the concentration of sTie2 decreased on the 7th day after resection and did not change statistically later on. The concentrations of Ang1 and sVEGF R1 did not change after the surgery. Lung cancer resection results in proangiogenic plasma protein changes that may stimulate tumor recurrences and metastases after early resection.

Download Full-text

Unsupervised Machine Learning of Radiomic Features for Predicting Treatment Response and Survival of Early-Stage Nonsmall Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.06.092 ◽

2017 ◽

Vol 99 (2) ◽

pp. S34 ◽

Cited By ~ 1

Author(s):

H. Li ◽

M. Galperin-Aizenberg ◽

D.A. Pryma ◽

C.B. Simone ◽

Y. Fan

Keyword(s):

Machine Learning ◽

Lung Cancer ◽

Radiation Therapy ◽

Treatment Response ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Stereotactic Body Radiation Therapy ◽

Early Stage ◽

Nonsmall Cell Lung Cancer ◽

Lung Cancer Patients

Download Full-text

MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer

Proceedings of the National Academy of Sciences ◽

10.1073/pnas.1502068112 ◽

2015 ◽

Vol 112 (31) ◽

pp. E4288-E4297 ◽

Cited By ~ 80

Author(s):

Ri Cui ◽

Wei Meng ◽

Hui-Lung Sun ◽

Taewan Kim ◽

Zhenqing Ye ◽

...

Keyword(s):

Lung Cancer ◽

Tumor Progression ◽

Cancer Patients ◽

Cell Lung Cancer ◽

Molecular Mechanisms ◽

Early Stage ◽

Nonsmall Cell Lung Cancer ◽

Disease Spread ◽

Lung Cancer Patients ◽

Resected Nsclc

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite advancements and improvements in surgical and medical treatments, the survival rate of lung cancer patients remains frustratingly poor. Local control for early-stage nonsmall cell lung cancer (NSCLC) has dramatically improved over the last decades for both operable and inoperable patients. However, the molecular mechanisms of NSCLC invasion leading to regional and distant disease spread remain poorly understood. Here, we identify microRNA-224 (miR-224) to be significantly up-regulated in NSCLC tissues, particularly in resected NSCLC metastasis. Increased miR-224 expression promotes cell migration, invasion, and proliferation by directly targeting the tumor suppressors TNFα-induced protein 1 (TNFAIP1) and SMAD4. In concordance with in vitro studies, mouse xenograft studies validated that miR-224 functions as a potent oncogenic miRNA in NSCLC in vivo. Moreover, we found promoter hypomethylation and activated ERK signaling to be involved in the regulation of miR-224 expression in NSCLC. Up-regulated miR-224, thus, facilitates tumor progression by shifting the equilibrium of the partially antagonist functions of SMAD4 and TNFAIP1 toward enhanced invasion and growth in NSCLC. Our findings indicate that targeting miR-224 could be effective in the treatment of certain lung cancer patients.

Download Full-text